Primarily among them are the drugs administered in the animal models of PD directed at the transcription factor erythroid factor 2-related nuclear factor 2 (Nrf2)/hemooxygenase-1 (HO-1) pathway, such as Ginalin A, fluprostenol, fucoxanthin, isoorientin [114] and idebenone, which, in cell cultures, demonstrated a transforming effect of the microglia activation state from M1 to M2 and decreased the progress of neurodegeneration in the mouse model of PD by inhibiting the MAPK and NF-κB signaling pathways [115]. The gene discussed is HMOX1; the disease is Parkinson disease.